Health TrialsbyHealthPanel

Validation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes

ConditionsType 2 Diabetes Mellitus (T2DM)Insulin ResistanceMetabolic Syndrome
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSalah Snouda

About this trial

This study tests a new tool called the Snouda Metabolic Score (SMS) that helps doctors identify the specific metabolic problems driving Type 2 Diabetes in each individual patient. Instead of treating all diabetic patients the same way, the SMS classifies patients into one of several metabolic phenotypes - patterns of dysfunction across five body systems: insulin resistance, chronic inflammation, hormonal disruption, gut microbiome imbalance, and mitochondrial dysfunction.

Once classified, each participant follows a personalized 24-week lifestyle and nutritional protocol targeting their specific phenotype. The protocol includes dietary changes, structured exercise, targeted nutritional supplements, and optional intermittent fasting. Participants track their blood glucose daily and complete biomarker blood tests at the start and end of the study.

The main goal is to determine whether the SMS tool accurately identifies metabolic phenotypes and whether phenotype-matched protocols produce better outcomes than standard approaches. The study measures changes in HbA1c, fasting insulin, C-peptide, inflammation markers, and whether participants achieve Type 2 Diabetes remission - defined as HbA1c below 6.5% without glucose-lowering medication.

The study is conducted entirely online through the diabetesreversal.io platform. There are no clinic visits required. Participants must be adults aged 18 or older with a confirmed Type 2 Diabetes diagnosis and must not be pregnant or breastfeeding.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed diagnosis of Type 2 Diabetes Mellitus (T2DM) by a licensed healthcare provider

Age 18 years or older

HbA1c between 6.5% and 11.0% at baseline

Currently managed with lifestyle measures alone, or with oral glucose-lowering medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or sulfonylureas)

Disqualifiers

Type 1 Diabetes Mellitus or Latent Autoimmune Diabetes in Adults (LADA)

Currently pregnant or breastfeeding

Currently using insulin therapy

Currently using GLP-1 receptor agonists (e.g., semaglutide, liraglutide)

Trial design

Design model

Single group

Treatments tested in this trial

  • Phenotype-Matched Dietary Protocol

    Behavioral

    A structured dietary plan tailored to the participant's SMS Confirmed Phenotype. Options include low-carbohydrate diet (Pillar A dominant), anti-inflammatory diet (Pillar B dominant), cortisol-regulating diet (Pillar C dominant), prebiotic/probiotic-rich diet (Pillar D dominant), or mitochondrial support diet (Pillar E dominant).

  • Structured Progressive Exercise Protocol

    Behavioral

    A progressive exercise program combining resistance training and aerobic activity, delivered through the diabetesreversal.io platform with instructional videos and weekly progression targets.

  • Targeted Nutritional Supplementation

    Dietary supplement

    Nutritional supplements selected based on the participant's SMS phenotype and identified deficiencies. May include magnesium, berberine, omega-3 fatty acids, vitamin D, CoQ10, or probiotic formulations depending on the Confirmed Phenotype.

  • Structured Intermittent Fasting Protocol

    Behavioral

    Optional structured intermittent fasting periods with a mandatory 24-hour fasting safety protocol including pre-fast physician consultation, 4-hourly glucose monitoring, defined stop criteria, and carbohydrate availability requirements.

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Phenotype-Matched Lifestyle InterventionExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Change in HbA1c from Baseline to Week 24

Change in glycated hemoglobin (HbA1c, %) measured via laboratory blood test at baseline and Week 24, as an indicator of long-term glycemic control improvement.

Time frame
Baseline and Week 24
2

Rate of Type 2 Diabetes Remission at Week 24

Proportion of participants achieving T2DM remission, defined as HbA1c below 6.5% without glucose-lowering medication for a minimum of 3 months, as assessed at Week 24.

Time frame
Week 24

Secondary outcomes

1

Change in Fasting Insulin from Baseline to Week 24

Time frame
Baseline and Week 24
2

Change in C-peptide from Baseline to Week 24

Time frame
Baseline and Week 24
3

Change in High-Sensitivity C-Reactive Protein (hs-CRP) from Baseline to Week 24

Time frame
Baseline and Week 24
4

Change in Fasting Morning Cortisol from Baseline to Week 24

Time frame
Baseline and Week 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Salah Snouda

Lead sponsor

Snouda Health Coaching Ltd

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: